← SynDRA
R-1487
SynDRA canonical compound SYN0024152 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
| Primary target(s) | MAPK14 |
| Mechanism of action | p38 MAPK inhibitor |
All known targets
Mechanisms of action (all sources)
- MAPK14 INHIBITOR
- MAP kinase p38 alpha inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- NLK
- GAK
- MAPK10
- MAPK11
- DDR1
- STK36
- MAPK8
- MAPK9
- RPS6KA3
- COQ8A
- RPS6KA4
- ABL1
- NTRK3
- NTRK1
- NTRK2
- PDPK1
- PAK1
- PAK4
- PBK
- PHKG2
- PIM1
- PIM2
- PIM3
- PKN2
- NEK4
- MET
- NEK2
- MKNK2
- MINK1
- MELK
- MATK
- MARK3
- MARK2
- MAPKAPK5
- MAPKAPK3
- MAPKAPK2
- MAPK13
- MAPK12
- MAPK1
- MAP4K5
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ALOX12
- GPX1
- KC1D
- KPCD2
- KPCD3
- LOX12
- M4K4
- MK01
- MK08
- MK09
Cross-references
Synonyms
- 6-(2,4-difluorophenoxy)-8-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
- UNII-IO0DCY55NQ
- IO0DCY55NQ
- CHEMBL1230122
- 6-(2,4-difluorophenoxy)-8-methyl-2-[(tetrahydro-2H-pyran-4-yl)amino]-Pyrido[2,3-d]pyrimidin-7(8H)-one
- 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2h-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8h)-one
- Kinome_3762
- SCHEMBL5120612
- KKKRKRMVJRHDMG-UHFFFAOYSA-N
- HMS3401C13
- BDBM50341342
- ZINC58633224
- AKOS027420928
- NCGC00262195-02
- KB-80224
- ACM449811921
- RefChem:178450
- R1487 cpd
- orb1299610
- SCHEMBL29527296
- ZSA81192
- EX-A14324
- NSC767348
- EBC-224062
- NSC-767348
- SDCCGRCH-0000039.P001
- NCGC00262195-03
- DB-070615
- CS-0003671
- T7667
- R1487?
- 3FN
- 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-D]pyrimidin-7(8H)-one
- C19H19ClF2N4O3
- R1487
- AC-35451
- R1487 (Hydrochloride)
- EX-A670
- 6-(2,4-Difluorophenoxy)-8-methyl-2-[(tetrahydro-2H-pyran-4-yl)amino]pyrido[2,3-d]pyrimidin-7(8H)-one hydrochloride
Look up R-1487 in the interactive SynDRA portal →